HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.

AbstractAIM:
To investigate molecular epidemiology of extended-spectrum β-lactamase/ESBL and plasmid-mediated AmpC β-lactamase/pAmpC producing Gram-negative bacteria causing urinary tract infections (UTIs) in Zenica-Doboj Canton, Bosnia and Herzegovina, in the period Decembar 2009-May 2010.
METHODS:
Antibiotic susceptibility was determined by disc diffusion and broth microdilution according to CLSI guidelines. Double-disk synergy test was performed in order to screen for ESBLs/pAmpC beta-lactamases. PCR was used to detect bla(ESBL)/bla(ampC)/bla(carb) genes. Genetic relatedness of the strains was determined by pulsed-field-gel-electrophoresis (PFGE).
RESULTS:
Among 85 patients with UTIs caused by ESBL producing isolates, 44 (51.8%) were from in-patients and 41 (48.2%) from outpatients. Klebsiella spp. was the most frequently isolated from in-patients, in 28 (63.6%) cases. Among outpatients, Klebsiella spp./Escherichia coli were the most frequently isolated, in 19 (46.3%)/16 (39.0%) cases. Twenty-one (75.0%) from hospital and nine (47.4%) from outpatient Klebsiella spp. isolates were positive for blaTEM, whereas 27 (96.4%) from in-patients and 6 (31.6%) from outpatient were bla(CTX-M) positive (18 hospital and five outpatient isolates were encoding bla(CTX-M-15)). One Klebsiella oxytoca and one Enterobacter cloacae inpatient isolates were positive for blaCTX-M-28. One Klebsiella pneumoniae outpatient isolate were positive for bla(CTX-M-22) and one E. coli for bla(CTX-M-3). One hospital Proteus mirabilis strain was positive for bla(CMY-2) and two Klebsiella spp. strains for blaDHA-1, whereas two E. coli, one K. oxytoca and one Proteus vulgaris outpatient strains were positive for bla(CMY-2).
CONCLUSION:
Identification of bla(CTX-M-3), bla(CTX-M-22) and bla(CTX-M-28) among Enterobacteriaceae is uncommon. In this study we report the emergency of CMY-2 and DHA-1 plasmid-mediated beta-lactamases.
AuthorsAmir Ibrahimagić, Branka Bedenić, Farah Kamberović, Selma Uzunović
JournalJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 21 Issue 5 Pg. 363-9 (May 2015) ISSN: 1437-7780 [Electronic] Netherlands
PMID25638292 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Bacterial Proteins
  • Escherichia coli Proteins
  • beta-lactamase CMY-2
  • beta-lactamase CTX-M-15
  • beta-lactamase CTX-M-3
  • AmpC beta-lactamases
  • CTX-M-28 beta-lactamase, Klebsiella pneumoniae
  • beta-Lactamases
  • beta-lactamase CTX-M-22, E coli
  • beta-lactamase DHA-1, Klebsiella pneumoniae
Topics
  • Ambulatory Care
  • Bacterial Proteins (genetics)
  • Bosnia and Herzegovina (epidemiology)
  • Citrobacter freundii (enzymology, genetics, isolation & purification)
  • Disk Diffusion Antimicrobial Tests
  • Electrophoresis, Gel, Pulsed-Field
  • Enterobacter cloacae (enzymology, genetics, isolation & purification)
  • Enterobacteriaceae (enzymology, genetics, isolation & purification)
  • Escherichia coli (enzymology, genetics, isolation & purification)
  • Escherichia coli Proteins (genetics)
  • Hospitalization
  • Humans
  • Infant
  • Klebsiella oxytoca (enzymology, genetics, isolation & purification)
  • Klebsiella pneumoniae (enzymology, genetics, isolation & purification)
  • Middle Aged
  • Molecular Epidemiology
  • Molecular Typing
  • Plasmids (genetics)
  • Prevalence
  • Proteus mirabilis (enzymology, genetics, isolation & purification)
  • Urinary Tract Infections (epidemiology, genetics, microbiology)
  • beta-Lactamases (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: